An update of Vaccine development against Entamoeba histolytica
DOI:
https://doi.org/10.47672/ejhs.715Keywords:
Parasitic infection, Immunization, Liver abscesses, Amoebiasis, Vaccine efficacy, Evasion, Vaccine candidates, Immunological memoryAbstract
Purpose: This review literature reveals designing of an effective vaccine against Entamoeba.histolytica, but due to some major limiting factors a successful vaccine has not been designed yet. The researches focusing on designing an ideal vaccine are summarized in this review literature. The major limiting factors leading to the failure of this particular vaccine are also discussed here
Methodology: This study is literature based focusing on recent advancement and contribution to vaccine designing. The epidemiology and pathogenesis of Entamoeba histolytica has been studied posing a major health threat. Some vaccines candidates and adjuvants have also been studied having promising results but require clinical trials.
Findings: The major finding in this review is less investment on tropical diseases and lack of long term immunity also needs to be elucidated. Various proteins associated with the chemical structure of Entamoeba histolytica are immunogenic and can be used as potential vaccine candidates. The interaction of Entamoeba histolytica with gut microbiota may result into new strains of the pathogen leading to evasion strategy of this particular parasite. In asymptomatic cases it colonizes the large intestine and sometimes spread to other soft organs of the body causing abscesses. Entamoeba histolytica can be transmitted through polluted water and food. The international transport of food materials may have a major role in Entamoeba histolytica transmission.
Recommendation: Further researches may be the base for an effective vaccine having long term immunological memory against Entamoeba histolytica. An effective vaccine may be effective in all age groups with no adverse effects. The improvement in hygiene and health care system may the possible ways of combating amoebiasis.
Downloads
References
Abd Alla, M. D., Wolf, R., White, G. L., Kosanke, S. D., Cary, D., Verweij, J. J., ... & Ravdin, J. I. (2012). Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and colitis in baboons (Papio sp.). Vaccine, 30(20), 3068-3075.
Abhyankar, M. M., Noor, Z., Tomai, M. A., Elvecrog, J., Fox, C. B., & Petri Jr, W. A. (2017). Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine, 35(6), 916-922.
Ahmed, R., & Gray, D. (1996). Immunological memory and protective immunity: understanding their relation. Science, 272(5258), 54-60.
Bansal, D., Malla, N., & Mahajan, R. C. (2006). Drug resistance in amoebiasis. Indian Journal of Medical Research, 123(2), 115.
Baxt, L. A., & Singh, U. (2008). New insights into Entamoeba histolytica pathogenesis. Current opinion in infectious diseases, 21(5), 489.
Begum, S., Quach, J., & Chadee, K. (2015). Immune evasion mechanisms of Entamoeba histolytica: progression to disease. Frontiers in microbiology, 6, 1394.
Bethony, J. M., Cole, R. N., Guo, X., Kamhawi, S., Lightowlers, M. W., Loukas, A., ... & Hotez, P. J. (2011). Vaccines to combat the neglected tropical diseases. Immunological reviews, 239(1), 237-270.
Chadee, K., Petri, W. A., Innes, D. J., & Ravdin, J. I. (1987). Rat and human colonic mucins bind to and inhibit adherence lectin of Entamoeba histolytica. The Journal of clinical investigation, 80(5), 1245-1254.
Cornick, S., & Chadee, K. (2017). Entamoeba histolytica: host parasite interactions at the colonic epithelium. Tissue Barriers, 5(1), e1283386.
Dolabella, S. S., Serrano-Luna, J., Navarro-García, F., Cerritos, R., Ximénez, C., Galván-Moroyoqui, J. M., ... & Shibayama, M. (2012). Amoebic liver abscess production by Entamoeba dispar. Annals of Hepatology, 11(1), 107-117.
Duc, P. P., Nguyen-Viet, H., Hattendorf, J., Zinsstag, J., Cam, P. D., & Odermatt, P. (2011). Risk factors for Entamoeba histolytica infection in an agricultural community in Hanam province, Vietnam. Parasites & vectors, 4(1), 1-9.
Flores, M. S., Obregón, A., Rangel, R., Tamez, E., Flores, A., Trejo‐Avila, L., ... & Galán, L. (2020). Glycans moieties in Entamoeba histolytica ubiquitin are immunodominant. Parasite Immunology, e12812.
Fonseca, Z., Díaz-Godínez, C., Mora, N., Alemán, O. R., Uribe-Querol, E., Carrero, J. C., & Rosales, C. (2018). Entamoeba histolytica induce signaling via Raf/MEK/ERK for neutrophil extracellular trap (NET) formation. Frontiers in cellular and infection microbiology, 8, 226.
França-Botelho, A. C., França, J. L., Oliveira, F. M., Franca, E. L., Honório-França, A. C., Caliari, M. V., & Gomes, M. A. (2011). Melatonin reduces the severity of experimental amoebiasis. Parasites & vectors, 4(1), 1-6.
Gaucher, D., & Chadee, K. (2003). Prospect for an Entamoeba histolytica Gal‐lectin‐based vaccine. Parasite immunology, 25(2), 55-58.
Gilchrist, C. A., & Petri Jr, W. A. (1999). Virulence factors of Entamoeba histolytica. Current opinion in microbiology, 2(4), 433-437.
Guo, X., Barroso, L., Lyerly, D. M., Petri Jr, W. A., & Houpt, E. R. (2011). CD4+ and CD8+ T cell-and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine. Vaccine, 29(4), 772-777.
Guzmán-Téllez, P., Martínez-Castillo, M., Flores-Huerta, N., Rosales-Morgan, G., Pacheco-Yépez, J., la Garza, M. D., ... & Shibayama, M. (2020). Lectins as virulence factors in Entamoeba histolytica and free-living amoebae. Future Microbiology, 15(10), 919-936.
Haque, R., Ali, I. M., Sack, R. B., Farr, B. M., Ramakrishnan, G., & Petri Jr, W. A. (2001). Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. The Journal of infectious diseases, 183(12), 1787-1793.
Hemmati, A., Hooshmand, E., & Hosseini, M. J. (2015). Identification of Entamoeba histolytica by molecular method in surface water of Rasht city, Iran. Iranian journal of public health, 44(2), 238.
Huang, S. H., Tsai, M. S., Lee, C. Y., Tsai, C. S., Liu, C. E., Lee, Y. T., ... & Taiwan HIV Study Group. (2020). Ongoing transmission of Entamoeba histolytica among newly diagnosed people living with HIV in Taiwan, 2009-2018. PLOS Neglected Tropical Diseases, 14(6), e0008400.
Hughes, S., & Kelly, P. (2006). Interactions of malnutrition and immune impairment, with specific reference to immunity against parasites. Parasite immunology, 28(11), 577.
Hung, C. C., Ji, D. D., Sun, H. Y., Lee, Y. T., Hsu, S. Y., Chang, S. Y., ... & Colebunders, R. (2008). Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl Trop Dis, 2(2), e175.
Huston, C. D., Houpt, E. R., Mann, B. J., Hahn, C. S., & Petri Jr, W. A. (2000). Caspase 3‐dependent killing of host cells by the parasite Entamoeba histolytica. Cellular microbiology, 2(6), 617-625.
Israeli, E., Agmon-Levin, N., Blank, M., & Shoenfeld, Y. (2009). Adjuvants and autoimmunity. Lupus, 18(13), 1217-1225.
Ivory, C. P., & Chadee, K. (2007). Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge. Infection and immunity, 75(10), 4917-4922.
Ivory, C. P., Keller, K., & Chadee, K. (2006). CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils. Infection and immunity, 74(1), 528-536.
Kantor, M., Abrantes, A., Estevez, A., Schiller, A., Torrent, J., Gascon, J., ... & Ochner, C. (2018). Entamoeba histolytica: updates in clinical manifestation, pathogenesis, and vaccine development. Canadian Journal of Gastroenterology and Hepatology, 2018.
Kantor, M., Abrantes, A., Estevez, A., Schiller, A., Torrent, J., Gascon, J., ... & Ochner, C. (2018). Entamoeba Histolytica: updates in clinical manifestation, pathogenesis, and vaccine development. Canadian Journal of Gastroenterology and Hepatology, 2018.
Kaur, U., Khurana, S., Saikia, U. N., & Dubey, M. L. (2013). Immunogenicity and protective efficacy of heparan sulphate binding proteins of Entamoeba histolytica in a guinea pig model of intestinal amoebiasis. Experimental parasitology, 135(3), 486-496.
Kawai, T., & Akira, S. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 34(5), 637-650.
Kelsall, B. L., & Ravdin, J. I. (1993). Degradation of human IgA by Entamoeba histolytica. Journal of infectious Diseases, 168(5), 1319-1322.
Kowalczyk, A., Doener, F., Zanzinger, K., Noth, J., Baumhof, P., Fotin-Mleczek, M., & Heidenreich, R. (2016). Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine, 34(33), 3882-3893.
Kumar, H., Kawai, T., & Akira, S. (2009). Pathogen recognition in the innate immune response. Biochemical Journal, 420(1), 1-16. Abhyankar, M. M., Orr, M. T., Lin, S., Suraju, M. O., Simpson, A., Blust, M., ... & Fox, C. B. (2018). Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica. npj Vaccines, 3(1), 1-10.
Lamm, M. E. (1997). Interaction of antigens and antibodies at mucosal surfaces. Annual review of microbiology, 51(1), 311-340.
Lamm, M. E. (1997). Interaction of antigens and antibodies at mucosal surfaces. Annual review of microbiology, 51(1), 311-340.
Lamm, M. E. (1998). IV. How epithelial transport of IgA antibodies relates to host defense. American Journal of Physiology-Gastrointestinal and Liver Physiology, 274(4), G614-G617.
Leder, K., Weller, P. F., & Ryan, E. T. (2014). Intestinal Entamoeba histolytica amebiasis.
Lejeune, M., Rybicka, J. M., & Chadee, K. (2009). Recent discoveries in the pathogenesis and immune response toward Entamoeba histolytica.
León-Sicairos, N., Reyes-López, M., Ordaz-Pichardo, C., & De La Garza, M. (2006). Microbicidal action of lactoferrin and lactoferricin ansd their synergistic effect with metronidazole in Entamoeba histolytica. Biochemistry and Cell Biology, 84(3), 327-336.
Mann, B. J. (2002). Structure and function of the Entamoeba histolytica Gal/GalNAc lectin. International review of cytology, 216, 59-80.
Mariotti, A. (2004). A primer on inflammation. Compendium of continuing education in dentistry (Jamesburg, NJ: 1995), 25(7 Suppl 1), 7-15.
Mendoza Cavazos, C., & Knoll, L. J. (2020). Entamoeba histolytica: Five facts about modeling a complex human disease in rodents. PLoS Pathogens, 16(11), e1008950.
Mendoza Cavazos, C., & Knoll, L. J. (2020). Entamoeba histolytica: Five facts about modeling a complex human disease in rodents. PLoS Pathogens, 16(11), e1008950.
Miller-Sims, V. C., & Petri Jr, W. A. (2002). Opportunities and obstacles in developing a vaccine for Entamoeba histolytica.
Mortimer, L., & Chadee, K. (2010). The immunopathogenesis of Entamoeba histolytica. Experimental parasitology, 126(3), 366-380.
Mukhopadhyay, M., Saha, A. K., Sarkar, A., & Mukherjee, S. (2010). Amoebic liver abscess: presentation and complications. Indian journal of surgery, 72(1), 37-41.
Nakada-Tsukui, K., & Nozaki, T. (2016). Immune response of amebiasis and immune evasion by Entamoeba histolytica. Frontiers in Immunology, 7, 175.
Nath, J., Ghosh, S. K., Singha, B., & Paul, J. (2015). Molecular epidemiology of amoebiasis: a cross-sectional study among North East Indian population. PLoS neglected tropical diseases, 9(12), e0004225.
Negi, S., Das, D. K., Pahari, S., Nadeem, S., & Agrewala, J. N. (2019). Potential role of gut microbiota in induction and regulation of innate immune memory. Frontiers in immunology, 10, 2441.
Netea, M. G., Joosten, L. A., Latz, E., Mills, K. H., Natoli, G., Stunnenberg, H. G., ... & Xavier, R. J. (2016). Trained immunity: a program of innate immune memory in health and disease. Science, 352(6284).
Orozco, E., Guarneros, G., Martinez-Palomo, A., & Sanchez, T. (1983). Entamoeba histolytica. Phagocytosis as a virulence factor. The Journal of experimental medicine, 158(5), 1511-1521.
Petri, W. A., & Ravdin, J. I. (1991). Protection of gerbils from amebic liver abscess by immunization with the galactose-specific adherence lectin of Entamoeba histolytica. Infection and immunity, 59(1), 97-101.
Pitman, R. S., & Blumberg, R. S. (2000). First line of defense: the role of the intestinal epithelium as an active component of the mucosal immune system. Journal of gastroenterology, 35(11), 805-814.
Quach, J., St-Pierre, J., & Chadee, K. (2014). The future for vaccine development against Entamoeba histolytica. Human vaccines & immunotherapeutics, 10(6), 1514-1521.
Quach, J., St-Pierre, J., & Chadee, K. (2014). The future for vaccine development against Entamoeba histolytica. Human vaccines & immunotherapeutics, 10(6), 1514-1521.
Que, X., & Reed, S. L. (2000). Cysteine proteinases and the pathogenesis of amebiasis. Clinical microbiology reviews, 13(2), 196-206.
Ramos, E., Olivos-García, A., Nequiz, M., Saavedra, E., Tello, E., Saralegui, A., ... & Tamayo, R. P. (2007). Entamoeba histolytica: apoptosis induced in vitro by nitric oxide species. Experimental parasitology, 116(3), 257-265.
Ravdin, J. I., Abd-Alla, M. D., Welles, S. L., Reddy, S., & Jackson, T. F. (2003). Intestinal antilectin immunoglobulin A antibody response and immunity to Entamoeba dispar infection following cure of amebic liver abscess. Infection and immunity, 71(12), 6899-6905.
Santi‐Rocca, J., Weber, C., Guigon, G., Sismeiro, O., Coppée, J. Y., & Guillén, N. (2008). The lysine‐and glutamic acid‐rich protein KERP1 plays a role in Entamoeba histolytica liver abscess pathogenesis. Cellular Microbiology, 10(1), 202-217.
Sehgal, D., Bhattacharya, A., & Bhattacharya, S. (1996). Pathogenesis of infection byEntamoeba histolytica. Journal of biosciences, 21(3), 423-432.
Shirley, D. A. T., Farr, L., Watanabe, K., & Moonah, S. (2018, July). A review of the global burden, new diagnostics, and current therapeutics for amebiasis. In Open forum infectious diseases (Vol. 5, No. 7, p. ofy161). US: Oxford University Press.
Shirley, D. A. T., Farr, L., Watanabe, K., & Moonah, S. (2018, July). A review of the global burden, new diagnostics, and current therapeutics for amebiasis. In Open forum infectious diseases (Vol. 5, No. 7, p. ofy161). US: Oxford University Press.
Singh, R. S., Walia, A. K., Kanwar, J. R., & Kennedy, J. F. (2016). Amoebiasis vaccine development: A snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin. International journal of biological macromolecules, 91, 258-268.
Tharmaratnam, T., Kumanan, T., Iskandar, M. A., D’Urzo, K., Gopee-Ramanan, P., Loganathan, M., ... & Tobbia, I. (2020). Entamoeba histolytica and amoebic liver abscess in northern Sri Lanka: a public health problem. Tropical Medicine and Health, 48(1), 1-13.
Ximénez, C., Morán, P., Rojas, L., Valadez, A., Gómez, A., Ramiro, M., ... & Oswaldo, P. (2011). Novelties on amoebiasis: a neglected tropical disease. Journal of Global Infectious Diseases, 3(2), 166.
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
